Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t-Reference-Cited by-同舟云学术

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

Published:2018-03-25 Issue:5 Volume:178 Page:1083-1101
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

de Bruin-Weller M.¹^ORCID,Thaçi D.²,Smith C.H.³,Reich K.⁴,Cork M.J.⁵,Radin A.⁶,Zhang Q.⁷,Akinlade B.⁶,Gadkari A.⁶,Eckert L.⁸,Hultsch T.⁹,Chen Z.⁶,Pirozzi G.¹⁰,Graham N.M.H.⁶,Shumel B.⁶

Affiliation:

1. University Medical Center Utrecht; Utrecht the Netherlands

2. University of Lübeck; Lübeck Germany

3. St. John's Institute of Dermatology; London U.K.

4. Dermatologikum and TFS Research Institute; Hamburg Germany

5. Sheffield Dermatology Research; The University of Sheffield; Sheffield U.K.

6. Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A.

7. Regeneron Pharmaceuticals, Inc.; Basking Ridge NJ U.S.A.

8. Sanofi; Chilly-Mazarin France

9. Sanofi; Cambridge MA U.S.A.

10. Sanofi; Bridgewater NJ U.S.A.

Funder